Loading clinical trials...
Loading clinical trials...
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Solvay Pharmaceuticals
NCT00599196 · Early Stage Parkinson's Disease
NCT00623324 · Early Stage Parkinson's Disease
NCT00269516 · Early Stage Parkinson's Disease
419
Birmingham, Alabama
413
Oceanside, California
408
Oxnard, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions